查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1304222

循环无细胞肿瘤DNA市场:肿瘤各类型，各癌症类型，各技术，各用途，各地区- 市场规模，占有率，展望，机会分析，2023年～2030年

Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 190 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场动态

扩大采用有机增长战略，例如市场主要参与者为扩大产品组合而推出的产品预计将在预测期内推动市场增长。

本调查的主要特征

  • 本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球循环无细胞肿瘤DNA市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
  • 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
  • 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
  • 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球循环无细胞肿瘤DNA市场的主要参与者之企业简介。
  • 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 全球循环无细胞肿瘤DNA市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以透过全球循环无细胞肿瘤DNA市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查目的与前提条件

  • 调查目的
  • 前提条件
  • 简称

第2章 市场概况

  • 报告概要
    • 市场定义和范围
  • 摘要整理
  • 连贯·机遇·地图(COM)

第3章 市场动态，法规，趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 主要的焦点
  • 产品销售
  • 技术的进步
  • PEST分析
  • 法规情势
  • 合併和收购

第4章 循环无细胞肿瘤DNA的全球市场:COVID-19影响分析

  • 经济影响
  • COVID-19流行病学
  • 供需的影响

第5章 循环无细胞肿瘤DNA的全球市场:肿瘤各类型，2018年-2030年

  • 恶性肿瘤
  • 前癌症肿瘤

第6章 循环无细胞肿瘤DNA的全球市场:各癌症类型，2018年～2030年

  • 肺癌症
  • 大肠癌症
  • 乳癌
  • 其他

第7章 循环无细胞肿瘤DNA的全球市场，各技术，2018年～2030年

  • PCR
  • 超并列序列
  • 一碱多型

第8章 循环无细胞肿瘤DNA的全球市场:各用途，2018年～2030年

  • 癌症诊断
  • 标靶治疗药
  • 预后预测

第9章 循环无细胞肿瘤DNA的全球市场:各地区，2018年～2030年

  • 北美
  • 美国
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他南美国家
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东
  • GCC
  • 以色列
  • 其他中东
  • 非洲
  • 北非
  • 中非
  • 南非

第10章 竞争情形

  • Biocept, Inc.
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • KURABO INDUSTRIES LTD
  • PerkinElmer chemagen Technologie GmbH
  • Biodesix
  • Guardant Health
  • QIAGEN
  • Sequenom, Inc.
  • Agilent Technologies, Inc.
  • Fluxion Biosciences Inc.
  • Natera, Inc.
  • Agena Bioscience, Inc.
  • Paragon Genomics, Inc.
  • Lucence Health Inc.
  • Eurofins Genomics
  • Thermo Fisher Scientific

第11章 章节(型材)

  • 调查手法
  • 关于出版社
简介目录
Product Code: CMI5819

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

  • This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

  • Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:
    • Malignant Tumors
    • Precancerous Tumors
  • Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Circulating Cell-Free Tumor DNA Market, By Technology:
    • PCR
    • Massively Parallel Sequencing
    • Single Nucleotide Polymorphism
  • Global Circulating Cell-Free Tumor DNA Market, By Application:
    • Cancer Diagnosis
    • Targeting Therapeutics
    • Prognosis Indication
  • Global Circulating Cell-Free Tumor DNA Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Biocept, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Illumina, Inc.
    • Quest Diagnostics Incorporated
    • KURABO INDUSTRIES LTD
    • PerkinElmer chemagen Technologie GmbH
    • Biodesix
    • Guardant Health
    • QIAGEN
    • Sequenom, Inc.
    • Agilent Technologies, Inc.
    • Fluxion Biosciences Inc.
    • Natera, Inc.
    • Agena Bioscience, Inc.
    • Paragon Genomics, Inc.
    • Lucence Health Inc.
    • Eurofins Genomics
    • Thermo Fisher Scientific

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Tumor Type
    • Market Snapshot, By Cancer Type
    • Market Snapshot, By Technology
    • Market Snapshot, By Application
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Highlights
  • Product Launch
  • Technological Advancements
  • PEST Analysis
  • Regulatory Scenario
  • Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Malignant Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Precancerous Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segments Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segments Trends
  • PCR
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Massively Parallel Sequencing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Single Nucleotide Polymorphism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Application, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Cancer Diagnosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Targeting Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Prognosis Indication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

9. Global Circulating Cell-free Tumor DNA Market, By Region, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Biocept, Inc.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • KURABO INDUSTRIES LTD
  • PerkinElmer chemagen Technologie GmbH
  • Biodesix
  • Guardant Health
  • QIAGEN
  • Sequenom, Inc.
  • Agilent Technologies, Inc.
  • Fluxion Biosciences Inc.
  • Natera, Inc.
  • Agena Bioscience, Inc.
  • Paragon Genomics, Inc.
  • Lucence Health Inc.
  • Eurofins Genomics
  • Thermo Fisher Scientific

11. Section

  • Research Methodology
  • About Us